TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03824665

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine Group
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group N:(Nalbuphine group)1 ml saline containing 4mg nalbuphine used instead of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Group
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group F: :(Fentanyl group)1 ml saline containing 20 μg fentanyl used instead of normal saline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: All patients received 8 ml of LAM which consisted of: 6 ml of ml of bupivacaine 0.5%, 1 ml of hyaluronidase containing 150 IU, 1 ml of additive~Patients were categorized into three groups according to the type of additive used with the LAM as follows:~Group C (Control group): included patients assigned to receive 1 ml normal saline.
Study: NCT00603759

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: celecoxib
Description: 100 mg qid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1 cap qid
Study: NCT03539250

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: IMRT with and without chemotherapy
Study: NCT04868812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy
Description: SmartXide 2 V 2 LR, MonaLisa Touch, DEKA, Florence, Italy; MonaLisa Touch CO2 fractionated laser
Study: NCT02797886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FES + VOL
Description: Electrical stimulation is applied in concert with the subject's volitional movement.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FES
Description: Electrical stimulation is applied to the subject while they are asked to do nothing.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VOL
Description: The subject initiates and completes the movement without electrical stimulation.
Study: NCT00394459

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perifix Epidural Anaesthesia Catheter
Description: Epidural Catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perifix Epidural Anaesthesia Catheter
Description: Epidural Catheter

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perifix Standard
Description: Perifix Standard

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Perifix New
Description: Perifix New
Study: NCT00630630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00512798

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341 (VELCADE)
Description: Dose Levels PS-341 (day 1)~* Level -1 0.7 mg/m2~* Level 1 1.0 mg/m2~* Level 2 1.0 mg/m2~* Level 3 1.3 mg/m2~* Level 4 1.5 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Temozolomide (day 8)~* Level - 1 50 mg/m2~* Level 1 50 mg/m2~* Level 2 75/mg/m2~* Level 3 75 mg/m2~* Level 4 75 mg/m2

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Not noted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PS-341 (VELCADE)
Description: 1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
Study: NCT02216461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of BIBW 2948 BS for oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medium dose of BIBW 2948 BS for oral inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of BIBW 2948 BS for oral inhalation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04354350

Intervention type: DRUG
Intervention: Ramipril
Description: Ramipril dispensing claim is used as the reference

Intervention type: DRUG
Intervention: Telmisartan
Description: Telmisartan dispensing claim is used as the exposure
Study: NCT05080010

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 cycles chemotherapy
Description: Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
Study: NCT01569685

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: Tablets, once a day, max 375 mg day (maximal recommended dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: Tablets, once a day, maximum 200 mg/day (maximum required dose)
Study: NCT03238287

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical chest compression
Description: In the application of advanced cardiac life support, chest compression is done with mechanical chest compression device. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manuel chest compression
Description: In the application of advanced cardiac life support, chest compression is done with hands. rSO2 measurements are used to detect the impact of the compression on brain perfusion. The application is performed in accordance with the recommendations on advanced cardiac life support in the current guidelines
Study: NCT05043467

Intervention type: DRUG
Intervention: Duvie(Lobeglitazone) tab 0.5mg
Description: patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018
Study: NCT03194373

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days~Maintenance Palbociclib:~Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (IV), dose= AUC 5, day= 1, cycle length: 21 days
Study: NCT02937350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D6-25-hydroxyvitamin D3
Description: Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
Study: NCT03277976

Intervention type: DEVICE
Intervention: PVI using ThermoCool® SmartTouch® Catheter
Description: PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index

Intervention type: DEVICE
Intervention: PVI using ThermoCool® SmartTouch® Catheter
Description: PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index

Intervention type: DEVICE
Intervention: PVI using ThermoCool® SmartTouch SF® Catheter
Description: PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index

Intervention type: DEVICE
Intervention: PVI using ThermoCool® SmartTouch SF® Catheter
Description: PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
Study: NCT01762852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg
Description: Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
Study: NCT02282644

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bone marrow sampling
Study: NCT01314716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZLI
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZLI
Description: AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AZLI administered via nebulizer three times daily
Study: NCT01348997

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Onward website + 16 person social network
Description: The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project Onward website + 8 person social network
Description: The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
Study: NCT00700271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg or 10 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg or 10 mg tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160 mg capsules.
Study: NCT00318760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 0.1 or 0.2 mg oral, one dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule 1 dose
Study: NCT00643643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 25 mg oral tablet once daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 50 mg oral tablet twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 100 mg oral tablet twice daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc (UK-427,857)
Description: 300 mg oral tablet twice daily for 10 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo oral tablet twice daily for 10 days
Study: NCT04299295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YVOIRE Y-Solution 360
Description: Hyaluronic acid dermal filler

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Juvéderm VOLBELLA
Description: Hyaluronic acid dermal filler
Study: NCT01738971

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid access
Description: Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: one month progestogen only pill
Description: Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
Study: NCT04247425

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Counseling
Description: Receive instructional guidance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Complete progressive resistance training
Study: NCT04428424

Intervention type: DRUG
Intervention: Enbrel
Description: As provided in real world practice
Study: NCT00826124

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural steroid injection
Description: Injection based solely on history and physical exam

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural steroid injection
Description: Two epidural steroid injections two weeks apart based on history, physical exam and MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Imaging of lumbar spine
Study: NCT04100330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ficlatuzumab
Description: Ficlatuzumab is a selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Cytarabine is a chemotherapy agent. Chemotherapy agents are medications that kill cancer cells.
Study: NCT00287625

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehabilitation
Description: Pulmonary rehabilitation
Study: NCT03544827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Atropine 0.01% then atropine 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Atropine 0.01% then atropine 0.1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Atropine 0.1% then atropine 0.01%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine
Description: Atropine 0.1% then atropine 0.01%
Study: NCT00002827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET cobalt-60 gamma ray therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET electron therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: low-LET photon therapy
Study: NCT04314440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: An accredited music therapist will deliver 15-20 minutes of music therapy every day, 4-5 days in week one and remaining in week two to all MT participants. All participants in music therapy group will get a total of nine sessions. The lullaby twinkle twinkle little star will be sung for \~5 minutes, followed by the same songs played on acoustic guitar for \~5 minutes and another \~5 minutes of the same song sung in voice. This protocol will be followed in all 9 sessions for all infants in the experimental arm. The sound levels will be maintained at 55-65 decibels (dB) using appropriate meters. If MT is interrupted within 10 minutes then a make-up session will be delivered, assuming no discharge. In case of missed sessions and interrupted session infants will receive a maximum of 12 session.
Study: NCT01564862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vortioxetine (Lu AA21004)
Description: Lu AA21004 capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Duloxetine capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching capsules
Study: NCT02191943

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Duraphat
Description: The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Icon approximal caries infiltration kit
Description: Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
Study: NCT01493336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine RTD
Description: single oral dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine [Xeloda]
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: standard treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine [Xeloda]
Description: standard treatment
Study: NCT04245020

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text message follow up
Description: A text message will be sent to the patient 6-8 weeks following discharge

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone follow up
Description: The patient will be followed up at 6-8 weeks following discharge with a telephone call

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In person follow up
Description: The patient will be followed up at 6-8 weeks following discharge in person in the outpatient department
Study: NCT03988556

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation using CareMin650 at 6 Joules (curative intent)
Description: CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation using CareMin650 at 6 Joules (curative intent)
Description: CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For curative treatment, the dose to be delivered has been set at 6J/cm2. If the lesions of patients included in a curative cohort are resolved before the end of the radiotherapy period, the treatment will be applied with a preventive aim and the dose will decrease from 6 to 3J/cm2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)
Description: CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation using CareMin650 at 3 Joules (prophylactic intent)
Description: CareMin650 is a photobiomodulation device which consists of a Lightbox and a light applicator to deliver red light with wavelength of 650 nm and irradiance between 10 and 50 mW/cm² to skin or mucosa.~For prophylactic treatment, the dose to be delivered has been set at 3J/cm2. If oral mucositis or radiodermatitis occurs in a patient included in a prophylactic cohort, the lesions will be treated with a curative intent and the dose will increase from 3 to 6J/cm2.
Study: NCT04090112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% lidocaine sprayed
Description: four puffs of 10% lidocaine sprayed at the cuff of ETT and four puffs at laryngeal inlet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% lidocaine intravenous
Description: 15 mg/kg of 2% lidocaine intravenous injection prior to extubation
Study: NCT03670953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR CD-LD
Description: Active comparator - IR CD-LD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IR CD-LD
Description: Active comparator - IR CD-LD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX203 ER CD-LD
Description: Investigational formulation - ER CD-LD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX203 ER CD-LD
Description: Investigational formulation - ER CD-LD

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Matching IPX203
Description: Double dummy placebo capsules

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Matching IR CD-LD
Description: Double dummy placebo tablets
Study: NCT03787472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational senofilcon A Multifocal Lens1
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational senofilcon A Multifocal Lens1
Description: CONTROL

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational senofilcon A Multifocal Lens2
Description: TEST

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJV Investigational senofilcon A Multifocal Lens2
Description: TEST